IRIDEX Corporation (Nasdaq: IRIX) today announced the receipt of an Issue Notification from the U.S. Patent and Trademark Office for U.S. Patent No. 7,766,904, "Adjustable Laser Probe For Use In Vitreoretinal Surgery." This patent applies to a number of consumable medical devices already in the IRIDEX product line, collectively identified and sold as Adjustable and Intuitive EndoProbe® laser handpieces.
The Adjustable Laser Probe speeds up treatments by allowing continuous adjustment of the optical fiber over a wide range of angles for full coverage of the peripheral retina without requiring removal and reinsertion of the probe from the eye.
"We continue to focus on ways to increase the value of our consumable instrumentation line by offering novel and creative product solutions to our ophthalmic customers which in turn will help us grow our business," stated Theodore A. Boutacoff, President and CEO, "and to reconfirm our corporate position as a leader in our market."
"The issuance of this patent is valuable to IRIDEX because it helps us maintain the differentiation of our vitreoretinal product line from those of our competitors, and we plan to capitalize on the leverage afforded by this new patent by expanding this product line in the near future."
AI-powered MRI predicts outcomes in prostate cancer